Rediscovering Trazodone for the Treatment of Major Depressive Disorder
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Trazodone is a triazolopyridine derivative that belongs to the class of serotonin receptor antagonists and reuptake inhibitors (SARIs). The drug is approved and marketed in several countries worldwide for the treatment of major depressive disorder (MDD) in adult patients. In clinical studies, trazodone has demonstrated comparable antidepressant activity to other drug classes, including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline (norepinephrine) reuptake inhibitors (SNRIs). Moreover, the SARI action of trazodone may overcome the tolerability issues that are often associated with second-generation antidepressants such as SSRIs (i.e. insomnia, anxiety and sexual dysfunction). Recent focus has been placed on the development of a new prolonged-release once-a-day formulation of trazodone (TzCOAD), which may provide improved tolerability over the conventional immediate-release formulation of trazodone. Clinical studies have led to the recent approval in the USA of TzCOAD (as Oleptro™; Angelini Labopharm LLC, Princeton, NJ, USA), which may see resurgence of interest in the drug for the management of patients with MDD. Although trazodone is approved for the treatment of depression, evidence supports the use of low-dose trazodone as an off-label hypnotic for the treatment of sleep disorders in patients with MDD. The most common adverse effects reported with trazodone are drowsiness (somnolence/sedation), headache, dizziness and dry mouth. Other events reported, albeit with low incidence, include orthostatic hypotension (particularly in elderly patients or those with heart disease), minimal anticholinergic activity, corrected QT interval prolongation and torsade de pointes, cardiac arrhythmias, and rare occurrences of priapism and suicidal ideation. Overall, trazodone is an effective and well tolerated antidepressant (SARI) with an important role in the current treatment of MDD both as monotherapy and as part of a combination strategy. Trazodone is effective in controlling a wide range of symptoms of depression, while avoiding the negative effects on sleep seen with SSRI antidepressants. The recently approved prolonged-release formulation should provide further optimization of this antidepressant and may be useful for enabling an appropriate therapeutic dose to be administered with improved patient compliance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“However, significant therapeutic limitations exist, including modest remission rates, often \50 % for both SSRIs and SNRIs [11], a relatively slow onset of efficacy [12] and variable efficacy across the spectrum of depressive symptoms [13].”
BackgroundPrevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542 · cited 1×
“Furthermore, adverse effects are common, including sexual dysfunction [14], weight gain/loss [15], insomnia/daytime sleepiness [16–18] and anxiety or nervousness [17].”
BackgroundStahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications
Stahl, S. M. (2021) · doi:10.1017/9781108975292 · Cited by 480
Residual symptoms in depressed patients who respond acutely to fluoxetine
Nierenberg, A. A., Keefe, B. R., Leslie, V. C., Alpert, J. E., Pava, J. A., Worthington, J. J., Rosenbaum, J. F., & Fava, M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0403 · Cited by 470 · cited 1×
“However, significant therapeutic limitations exist, including modest remission rates, often \50 % for both SSRIs and SNRIs [11], a relatively slow onset of efficacy [12] and variable efficacy across the spectrum of depressive symptoms [13].”
BackgroundMajor Depressive Disorder Treatment Guidelines in America and Europe
Davidson, J. R. T. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.9058se1c.04gry · Cited by 344
A Review of the Evidence for the Efficacy and Safety of Trazodone in Insomnia
Mendelson, W. B. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0409 · Cited by 308
Marek, G. J., Carpenter, L. L., McDougle, C. J., & Price, L. H. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300057 · Cited by 275
Trazodone for antidepressant-associated insomnia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.7.1069 · Cited by 227
A Comparison of Venlafaxine, Trazodone, and Placebo in Major Depression
CUNNINGHAM, L. A., BORISON, R. L., CARMAN, J. S., CHOUINARD, G., CROWDER, J. E., DIAMOND, B. I., FISCHER, D. E., & HEARST, E. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199404000-00003 · Cited by 159
Effects of trazodone on the sleep of depressed subjects—a polygraphic study
Mouret, J., Lemoine, P., Minuit, M. P., Benkelfat, C., & Renardet, M. (1988) · Psychopharmacology · doi:10.1007/bf00172629 · Cited by 116
Effects of trazodone on EEG sleep and clinical state in major depression
van Bemmel, A. L., Havermans, R. G., & van Diest, R. (1992) · Psychopharmacology · doi:10.1007/bf02245272 · Cited by 67
The future of psychopharmacology of depression.
Chang, T., & Fava, M. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06223blu · Cited by 50 · cited 1×
“SSRIs and their derivative compounds, the serotonin-noradrenaline (norepinephrine) reuptake inhibitors (SNRIs) and noradrenaline reuptake inhibitors (NERIs), have since been shown to be comparable in efficacy and more tolerable than older agents such as tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors…”
BackgroundBlacker, R., Shanks, N. J., Chapman, N., & Davey, A. (1988) · Psychopharmacology · doi:10.1007/bf00172625 · Cited by 39
Moon, C. A. L., & Davey, A. (1988) · Psychopharmacology · doi:10.1007/bf00172623 · Cited by 27
Cited by
Psychiatric Disorders and Sleep Issues
Sutton, E. L. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.06.009 · Cited by 119
The molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
Effects of trazodone on behavioral signs of stress in hospitalized dogs
Gilbert-Gregory, S. E., Stull, J. W., Rice, M. R., & Herron, M. E. (2016) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.249.11.1281 · Cited by 97
The PERK-Dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases
Rozpędek-Kamińska, W., Siwecka, N., Wawrzynkiewicz, A., Wojtczak, R., Pytel, D., Diehl, J. A., & Majsterek, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062108 · Cited by 84
Update of sleep alterations in depression.
Medina, A. B., Lechuga, D. A., Escandón, O. S., & Moctezuma, J. V. (2014) · Sleep Science · doi:10.1016/j.slsci.2014.09.015 · Cited by 65
Metadata
- Authors
- Fagiolini, A., Comandini, A., Dell’Osso, M. C., & Kasper, S.
- Venue
- CNS Drugs
- Published
- 2012-10-13
- Volume
- 26
- Issue
- 12
- Pages
- 1033-1049
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2125553099
- Cited by
- 228
- References
- 14
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.